WO1996003142A1 - Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale - Google Patents

Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale Download PDF

Info

Publication number
WO1996003142A1
WO1996003142A1 PCT/GB1995/001735 GB9501735W WO9603142A1 WO 1996003142 A1 WO1996003142 A1 WO 1996003142A1 GB 9501735 W GB9501735 W GB 9501735W WO 9603142 A1 WO9603142 A1 WO 9603142A1
Authority
WO
WIPO (PCT)
Prior art keywords
delivery composition
icam
microspheres
chitosan
composition according
Prior art date
Application number
PCT/GB1995/001735
Other languages
English (en)
Inventor
Peter Watts
Lisbeth Illum
Original Assignee
Danbiosyst Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Limited filed Critical Danbiosyst Uk Limited
Priority to GB9700817A priority Critical patent/GB2305606B/en
Priority to AU29886/95A priority patent/AU707462C/en
Priority to JP8505576A priority patent/JPH10506376A/ja
Priority to EP95925947A priority patent/EP0773791A1/fr
Publication of WO1996003142A1 publication Critical patent/WO1996003142A1/fr
Priority to NO970252A priority patent/NO970252D0/no
Priority to FI970331A priority patent/FI970331A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Composition d'apport de médicament destinée à l'administration par voie nasale comprenant l'agent antiviral ICAM-1 et une matière bioadhésive. La matière bioadhésive peut être une solution de chitosane, une formulation liquide comprenant une matière polymère ou une pluralité de microsphères bioadhésives. La matière polymère est de préférence de la gomme de gellane ou de l'alginate. Les microsphères peuvent être formées avec l'amidon, du chitosane, de l'acide hyaluronique ou de la gélatine.
PCT/GB1995/001735 1994-07-26 1995-07-24 Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale WO1996003142A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB9700817A GB2305606B (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of ICAM-1
AU29886/95A AU707462C (en) 1994-07-26 1995-07-24 Drug delivery composition for the nasal administration of antiviral agents
JP8505576A JPH10506376A (ja) 1994-07-26 1995-07-24 薬剤移送用組成物および薬剤投与方法
EP95925947A EP0773791A1 (fr) 1994-07-26 1995-07-24 Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale
NO970252A NO970252D0 (no) 1994-07-26 1997-01-21 Blanding for nasal administrering av et medikament
FI970331A FI970331A0 (fi) 1994-07-26 1997-01-27 Lääkkeen antokoostumus virustenvastaisten aineiden nenään toteutettavaa antoa varten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414966.3 1994-07-26
GB9414966A GB9414966D0 (en) 1994-07-26 1994-07-26 Pharmaceutical compositions for the nasal administration of antiviral agents

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08776470 A-371-Of-International 1997-03-28
US09/848,600 Continuation US20010053359A1 (en) 1994-07-26 2001-05-03 Drug delivery composition for the nasal administration of antiviral agents

Publications (1)

Publication Number Publication Date
WO1996003142A1 true WO1996003142A1 (fr) 1996-02-08

Family

ID=10758832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001735 WO1996003142A1 (fr) 1994-07-26 1995-07-24 Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale

Country Status (7)

Country Link
EP (1) EP0773791A1 (fr)
JP (1) JPH10506376A (fr)
CA (1) CA2195639A1 (fr)
FI (1) FI970331A0 (fr)
GB (2) GB9414966D0 (fr)
NO (1) NO970252D0 (fr)
WO (1) WO1996003142A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032596A1 (fr) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation en poudre de molecules a adhesion intracellulaire
EP0833614A1 (fr) * 1995-06-07 1998-04-08 Sri International Systeme et procede de production de microparticules chargees de medicaments
WO1998030207A1 (fr) * 1997-01-14 1998-07-16 Danbiosyst Uk Limited Microparticules a base de chitosane et de gelatine de type a
WO1999022768A1 (fr) * 1997-10-31 1999-05-14 Monsanto Company Composition a liberation lente comprenant des gels a gomme gellane
EP0994700A1 (fr) * 1997-07-18 2000-04-26 Bayer Corporation Procedes d'elimination de solvant residuel dans les compositions medicamenteuses administrees par voie nasale
JP2001524509A (ja) * 1997-12-02 2001-12-04 ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド 鼻孔投与用組成物
WO2002000268A1 (fr) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Compositions de soins des plaies pulverisables
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
WO2005079749A3 (fr) * 2004-02-21 2006-03-23 Cal Res Ct Ltd West Pharmaceut Solution contenant du chitosane
WO2008091588A1 (fr) 2007-01-22 2008-07-31 Targacept, Inc. Administration intranasale, buccale ou sublinguale d'analogues de métanicotine
JP2009079052A (ja) * 1997-04-18 2009-04-16 Archimedes Development Ltd 粘膜表面への改良された薬物供給
DE102008007759A1 (de) 2007-12-04 2009-06-18 Atlantichem Gmbh Mittel zum Verhindern von Verfärbungen beim Waschen von Textilien
US7947257B2 (en) 2003-12-05 2011-05-24 Archimedes Development Limited Method of intranasal administration of granisetron
US8216604B2 (en) 2003-01-10 2012-07-10 Archimedes Development Limited Method of managing or treating pain

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (fr) * 1987-11-02 1989-05-10 Baylor College Of Medicine Utilisation du ICAM-1 ou de ses derivés fonctionels pour le traitement des inflammations non spécifiques
EP0362531A1 (fr) * 1988-09-01 1990-04-11 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
WO1990005522A1 (fr) * 1988-11-17 1990-05-31 Per Prisell Preparation pharmaceutique
WO1991006282A1 (fr) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Compositions pharmacologiques a particules de taille reduite
WO1993006842A1 (fr) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Utilisation de molecules d'adhesion intercellulaire et de leurs ligands de liaison dans le traitement de l'asthme
WO1994000485A1 (fr) * 1992-06-22 1994-01-06 Miles Inc. Formes multimeres de la proteine propre au recepteur du rhinovirus humain
WO1994027576A1 (fr) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Composition d'administration par voie nasale d'un medicament, contenant de la nicotine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863A2 (fr) * 1987-11-02 1989-05-10 Baylor College Of Medicine Utilisation du ICAM-1 ou de ses derivés fonctionels pour le traitement des inflammations non spécifiques
EP0362531A1 (fr) * 1988-09-01 1990-04-11 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
WO1990005522A1 (fr) * 1988-11-17 1990-05-31 Per Prisell Preparation pharmaceutique
WO1991006282A1 (fr) * 1989-11-04 1991-05-16 Danbiosyst Uk Limited Compositions pharmacologiques a particules de taille reduite
WO1993006842A1 (fr) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Utilisation de molecules d'adhesion intercellulaire et de leurs ligands de liaison dans le traitement de l'asthme
WO1994000485A1 (fr) * 1992-06-22 1994-01-06 Miles Inc. Formes multimeres de la proteine propre au recepteur du rhinovirus humain
WO1994027576A1 (fr) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Composition d'administration par voie nasale d'un medicament, contenant de la nicotine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L. ILLUM: "The nasal delivery of peptides and proteins.", TRENDS IN BIOTECHNOLOGY, vol. 9, no. 8, CAMBRIDGE, GB, pages 284 - 289 *
S MARLIN ET AL.: "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection.", NATURE, vol. 344, 1 March 1990 (1990-03-01), LONDON, GB, pages 70 - 72 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0833614A1 (fr) * 1995-06-07 1998-04-08 Sri International Systeme et procede de production de microparticules chargees de medicaments
US7087245B2 (en) 1995-06-07 2006-08-08 Bomberger David C ICAM-1 formulation having controlled-size microparticles
EP0833614A4 (fr) * 1995-06-07 2001-07-11 Stanford Res Inst Int Systeme et procede de production de microparticules chargees de medicaments
WO1997032596A1 (fr) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation en poudre de molecules a adhesion intracellulaire
US6465626B1 (en) 1997-01-14 2002-10-15 West Pharmaceutical Services Drug Delivery And Clincal Research Centre, Limited Pharmaceutical compositions of chitosan with type-A gelatin
WO1998030207A1 (fr) * 1997-01-14 1998-07-16 Danbiosyst Uk Limited Microparticules a base de chitosane et de gelatine de type a
GB2335357A (en) * 1997-01-14 1999-09-22 Danbiosyst Uk Chitosan-gelatin A microparticles
GB2335357B (en) * 1997-01-14 2000-12-13 Danbiosyst Uk Ltd Chitosan-gelatin a microparticles
JP2009079052A (ja) * 1997-04-18 2009-04-16 Archimedes Development Ltd 粘膜表面への改良された薬物供給
EP0994700A4 (fr) * 1997-07-18 2000-10-18 Bayer Ag Procedes d'elimination de solvant residuel dans les compositions medicamenteuses administrees par voie nasale
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP0994700A1 (fr) * 1997-07-18 2000-04-26 Bayer Corporation Procedes d'elimination de solvant residuel dans les compositions medicamenteuses administrees par voie nasale
WO1999022768A1 (fr) * 1997-10-31 1999-05-14 Monsanto Company Composition a liberation lente comprenant des gels a gomme gellane
AU744328B2 (en) * 1997-10-31 2002-02-21 Cp Kelco Aps Controlled release compositions comprising gellan gum gels
JP2001524509A (ja) * 1997-12-02 2001-12-04 ウエスト・ファーマシューティカル・サービセズ・ドラッグ・デリバリー・アンド・クリニカル・リサーチ・センター・リミテッド 鼻孔投与用組成物
JP4754067B2 (ja) * 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
WO2002000268A1 (fr) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Compositions de soins des plaies pulverisables
GB2378383A (en) * 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US8216604B2 (en) 2003-01-10 2012-07-10 Archimedes Development Limited Method of managing or treating pain
US8889176B2 (en) 2003-01-10 2014-11-18 Depomed, Inc. Method of managing or treating pain
US9078814B2 (en) 2003-01-10 2015-07-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US9814705B2 (en) 2003-01-10 2017-11-14 Depomed, Inc. Intranasal spray device containing pharmaceutical composition
US7947257B2 (en) 2003-12-05 2011-05-24 Archimedes Development Limited Method of intranasal administration of granisetron
WO2005079749A3 (fr) * 2004-02-21 2006-03-23 Cal Res Ct Ltd West Pharmaceut Solution contenant du chitosane
WO2008091588A1 (fr) 2007-01-22 2008-07-31 Targacept, Inc. Administration intranasale, buccale ou sublinguale d'analogues de métanicotine
DE102008007759A1 (de) 2007-12-04 2009-06-18 Atlantichem Gmbh Mittel zum Verhindern von Verfärbungen beim Waschen von Textilien

Also Published As

Publication number Publication date
EP0773791A1 (fr) 1997-05-21
GB2305606B (en) 1998-08-05
GB2305606A (en) 1997-04-16
NO970252L (no) 1997-01-21
GB9414966D0 (en) 1994-09-14
GB9700817D0 (en) 1997-03-05
NO970252D0 (no) 1997-01-21
AU707462B2 (en) 1999-07-08
JPH10506376A (ja) 1998-06-23
CA2195639A1 (fr) 1996-02-08
AU2988695A (en) 1996-02-22
FI970331A (fi) 1997-01-27
FI970331A0 (fi) 1997-01-27

Similar Documents

Publication Publication Date Title
US20010053359A1 (en) Drug delivery composition for the nasal administration of antiviral agents
Barclay et al. Review of polysaccharide particle-based functional drug delivery
EP0697858B1 (fr) Composition d'administration par voie nasale d'un medicament, contenant de la nicotine
WO1996003142A1 (fr) Composition d'apport de medicament utile pour administrer des agents antiviraux par voie orale
Gåserød et al. The enhancement of the bioadhesive properties of calcium alginate gel beads by coating with chitosan
Rassu et al. Composite chitosan/alginate hydrogel for controlled release of deferoxamine: A system to potentially treat iron dysregulation diseases
Coviello et al. Polysaccharide hydrogels for modified release formulations
Harding et al. Biopolymer mucoadhesives
US6207197B1 (en) Gastroretentive controlled release microspheres for improved drug delivery
Kas Chitosan: properties, preparations and application to microparticulate systems
Dumitriu et al. Polymeric biomaterials
Tønnesen et al. Alginate in drug delivery systems
JPH04503508A (ja) 薬物送達組成物
JP2009537597A (ja) アニオン性及びカチオン性多糖類のポリマー混合物並びにその使用
JP2009511549A (ja) キトサンおよびヘパリンナノ粒子
Valente et al. Polysaccharide-based formulations as potential carriers for pulmonary delivery–a review of their properties and fates
AU6219599A (en) Formulations of fexofenadine
JP2003525980A (ja) ヒアルロン酸誘導体により形成されるクラスレート錯体と医薬としてのその用途
Shariatinia Biopolymeric nanocomposites in drug delivery
WO2018185321A1 (fr) Renforcement des propriétés barrière de mucus
Manna et al. Marine polysaccharides in tailor-made drug delivery
Banerjee et al. Structure and drug delivery relationship of acidic polysaccharides: a review
AU707462C (en) Drug delivery composition for the nasal administration of antiviral agents
Pelin et al. Mucoadhesive buccal drug delivery systems containing polysaccharides
Kumar et al. Polysaccharide nanoconjugates for drug solubilization and targeted delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995925947

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2195639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 970331

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 1997 776470

Country of ref document: US

Date of ref document: 19970328

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995925947

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995925947

Country of ref document: EP